Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advices CapMan on acquisition of Nacka Närsjukhus Proxima
Mandate

Vinge advices CapMan on acquisition of Nacka Närsjukhus Proxima

June 28, 2007

Vinge is advising funds managed by CapMan on the acquisition of Nacka Närsjukhus Proxima. Nacka Närsjukhus Proxima is a modern healthcare provider that offers specialised healthcare services from emergency unit to complex surgery within various specialities, such as orthopaedics. The company serves primarily the greater Stockholm area and the Stockholm County Council as well as other county councils in Sweden. The transaction is subject to regulatory approvals and other customary closing conditions.

The Vinge team advising CapMan includes partners Jan Byström, and Ulf Sallnäs and associates Mats Hävermark, Philip Asmar, Johanna Rutberg and Per Westman. Partner Mikael Ståhl advises CapMan on the financing of the acquisition. Partner Johan Karlsson and associate Emma Nörler provide competition law advice.

Related

Vinge advises Trianon in connection with directed share issue and tender offer for subordinated sustainable capital securities

 Vinge advises Fastighets Aktiebolaget Trianon (publ) in connection with a directed share issue of SEK 184 million and a tender offer for outstanding subordinated perpetual floating rate callable sustainable capital securities.
April 19, 2024

Vinge advises Blackstone in connection with its investment in Winthrop Technologies

 Vinge, as local Swedish counsel, advised Blackstone Tactical Opportunities and affiliated funds (“Blackstone”) in connection with a strategic partnership with Winthrop Technologies Limited (“Winthrop Technologies”).
April 17, 2024

Vinge has advised Hansa Biopharma in connection with a directed share issue of SEK 372 million

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of SEK 372 million before transaction costs. Hansa Biopharma is a commercial-stage biopharmaceutical company pioneering the development and commercialization of innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa Biopharma’s ordinary share is listed on Nasdaq Stockholm.
April 16, 2024